S&C Advises Amgen in $28.3 Billion Acquisition of Horizon Therapeutics 

December 12, 2022

In the largest healthcare merger announced this year, Amgen has agreed to acquire Horizon Therapeutics for an enterprise value of $28.3 billion. The all-cash deal was announced December 12.
Amgen is one of the world's leading independent biotechnology companies. Horizon Therapeutics is a global biotechnology company headquartered in Dublin, Ireland and is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases.
The cross-border S&C team advising Amgen includes Frank Aquila, Miaoting (Mimi) Wu, Spencer Nord and Andrew Kim. Ben Perry, Prateek Andharia and Catherine McLaughlin are advising on Takeover Panel matters. Ari Blaut, Presley Warner, Joyce Kwok, Matthew Squire, Hannah Cockle and Dermot Costello are advising on finance matters. Heather Coleman and Rebecca Rabinowitz are advising on executive compensation. Davis Wang, HyunKyu Kim and Stephen Profeta are advising on tax matters. Nader A. Mousavi, RuiHui (Rachel) Yu, KJ Lim, Jamie Chang, Elizabeth Levin and Elianne Neuman Schiff are advising on intellectual property matters. Renata Hesse, Michael Rosenthal, Alexander Minore, Matt Bogdan and Marielena Doeding are advising on competition matters.